TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed signals. While there are improvements in losses and cash flexibility, the reduced guidance and uncertainties due to organizational changes and external factors like weather impact sentiment negatively. The Q&A highlighted management's cautious approach and lack of clarity in some responses, further contributing to a neutral outlook. The absence of strong positive catalysts or partnerships limits the potential for a significant stock price increase.
Key Financial Performance
Revenue for Q4 2025 $20.9 million, an 18% increase year-over-year. Growth was driven by new customers, international sales growth, and the U.S. launch of larger PRS units. However, growth was partially offset by a mix shift in the hernia product line towards smaller-sized IHR units.
Full Year 2025 Revenue $80.3 million, a 16% increase year-over-year. Revenue from OviTex grew 12%, and OviTex PRS grew 20%. Growth was attributed to new customers, international sales, and the U.S. launch of larger PRS units, partially offset by a mix shift in the hernia product line.
OviTex Unit Sales Grew 20% for Q4 2025 and 22% for the full year. Growth was driven by increased adoption and product demand.
PRS Unit Sales Grew 12% for both Q4 2025 and the full year. Growth was attributed to the U.S. launch of larger PRS units.
LIQUIFIX Revenue More than tripled in Q4 2025 compared to Q4 2024, reflecting early commercial traction and expanded adoption alongside the OviTex portfolio.
European Sales $12.1 million in 2025, a 17% increase from $10.3 million in 2024. Growth was driven by traction in key markets and continued investment in expanding access globally.
Gross Margin 66% for Q4 2025 and 68% for the full year, compared to 64% and 67% in the prior year periods, respectively. Improvement was driven by lower excess and obsolete inventory expense as a percentage of revenue.
Sales and Marketing Expenses $14.5 million for Q4 2025 and $63.2 million for the full year, compared to $14 million and $64.6 million in the prior year periods. The increase in Q4 was due to higher commissions from stronger revenue, while the full year saw lower compensation, severance, consulting, and travel costs.
General and Administrative Expenses $3.8 million for Q4 2025 and $15.7 million for the full year, compared to $3.6 million and $14.7 million in the prior year periods. The increase was attributed to general operational costs.
R&D Expenses $2.1 million for Q4 2025 and $9.2 million for the full year, compared to $2 million and $8.8 million in the prior year periods. The increase was due to ongoing research and development activities.
Loss from Operations $6.6 million for Q4 2025 and $33.8 million for the full year, compared to $8.4 million and $34.1 million in the prior year periods. The improvement was due to revenue growth and operating discipline.
Net Loss $9 million for Q4 2025 and $38.8 million for the full year, compared to $9.2 million and $37.8 million in the prior year periods. The slight improvement was due to revenue growth and cost management.
Cash and Cash Equivalents $50.8 million at the end of 2025, reflecting strengthened financial flexibility through refinancing debt and raising equity capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
OviTex LTR launch: Introduced a new addition to the portfolio offering durable support during healing and providing surgeons with a tissue-based alternative to synthetic mesh.
LIQUIFIX adoption: LIQUIFIX revenue more than tripled over the fourth quarter of 2024, reflecting early commercial traction and expanded adoption alongside the core OviTex portfolio.
European market growth: European sales accounted for 15% of total revenue ($12.1 million in 2025), a 17% increase from $10.3 million in 2024. Rapid adoption of OviTex in the U.K. and the Netherlands was noted.
U.S. market expansion: Achieved record fourth-quarter revenues and expanded the U.S. sales team to 88 quota-carrying territory managers, with a focus on deeper penetration in target accounts.
Commercial team restructuring: Redesigned the U.S. commercial leadership team, implemented a new sales general manager structure, and upgraded five key senior roles to improve accountability and execution.
Sales enablement tools: Developed and rolled out new sales enablement technology to prioritize and target sales activity more effectively.
Sales training and recruitment: Accelerated hiring and invested in training programs to reduce the time between hiring and commercial effectiveness. Approximately 40% of the U.S. field team joined in the last two quarters.
Focus on product innovation: Committed to offering the best soft tissue reconstruction product portfolio and announced plans for additional product launches in 2026.
Clinical trial for hiatal hernia: Enrolled the first patients in the ECHO trial to strengthen clinical evidence and access alternative surgeon call points.
European market investment: Purposeful investment plan to expand presence within Continental Europe, aiming for meaningful growth contribution in the coming years.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Commercial Reorganization: The company underwent a significant commercial reorganization in 2025, which could have caused disruption in productivity and growth. While this was managed effectively, the inherent risks of such large-scale changes include potential misalignment, slower ramp-up of new hires, and challenges in maintaining momentum.
Sales Team Expansion: 40% of the sales team joined in the last 6 months, which presents risks related to onboarding, training, and achieving full productivity. The reliance on new hires to meet 2026 targets could lead to underperformance if ramp-up periods are longer than expected.
Market Competition: In Europe, the competitive market dynamics, including pricing and bundling, pose challenges. While the company has seen success in the U.K. and Netherlands, expanding into other European markets may face hurdles due to established competitors and differing market conditions.
Product Mix Shift: There was a mix shift in the hernia product line, with increased sales of smaller-sized IHR units, which could impact revenue growth if higher-margin products do not gain traction.
Economic and Financial Risks: The company reported a net loss of $38.8 million for 2025 and continues to operate at a loss. While steps have been taken to strengthen the balance sheet, sustained losses could impact long-term financial stability.
Regulatory and Clinical Risks: The company is conducting a hiatal hernia trial (ECHO) to strengthen clinical evidence. Delays or unfavorable outcomes in this trial could hinder market access and adoption of related products.
Operational Execution: The company has implemented new sales enablement tools and compensation plans. However, the effectiveness of these changes in driving deeper penetration and sustainable growth remains to be proven.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For full year 2026, the company anticipates revenue growth of at least 8% over 2025, with Q1 2026 revenue expected to be approximately $18.5 million.
Commercial Team Expansion: The U.S. sales team has reached 88 quota-carrying territory managers, with plans to maintain this level for 2026. The team is expected to contribute incrementally each quarter as new hires ramp up productivity.
European Market Expansion: The company plans to expand its presence within Continental Europe, viewing it as a meaningful contributor to growth in the coming years.
Product Launches: Additional product launches are anticipated throughout 2026 to drive greater market share in the U.S. market.
Sales Strategy: The 2026 compensation program is designed to incentivize deeper penetration in target accounts, focusing on sustainable recurring revenue opportunities.
Clinical Trials: The company has enrolled the first patients in its hiatal hernia trial, which aims to strengthen clinical evidence and expand access to alternative surgeon call points.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why was the fiscal year top-line guidance set at 8%, which is below the Q3 call's expectations?
A:The guidance was set at 8% due to wholesale changes across the organization, including hiring new sales reps and restructuring territories. Management wanted to be prudent, considering the 6-9 month breakeven period for new Territory Managers and the complexity of contract implementation. They also emphasized the importance of giving the new reps time to mature and drive results.
Q:What is the expected cadence for the fiscal year?
A:The cadence is expected to follow a pattern similar to prior years, with a step-up from Q1 to Q2, a smaller step-up from Q2 to Q3 due to summer holidays, and a larger step-up from Q3 to Q4. This pattern will be slightly amplified by the addition of new sales reps who will become productive in about 6 months.
Q:What are the expectations for contracting and execution in 2026?
A:Management emphasized a shift in focus from signing new contracts to executing existing agreements. They acknowledged the complexity of contract implementation, which varies by hospital, and highlighted the need to translate signed agreements into patient revenue.
Q:What factors contributed to the Q1 guidance being lower than expected?
A:The lower Q1 guidance was attributed to structural changes in the commercial organization, including territory restructuring and focusing on sales force efficiency. Additionally, external factors like low volumes in January and February and weather disruptions impacted elective procedures.
Q:What is the long-term growth outlook for TELA Bio?
A:Management expects to significantly outgrow the mid-single-digit market growth rates. They anticipate returning to double-digit growth or beyond in the second half of the year, driven by comprehensive organizational changes and new product launches.
Q:When are ASPs for hernia expected to stabilize?
A:ASPs for hernia are influenced by the mix of procedures (e.g., ventral, inguinal, hiatal) and the shift towards robotic and laparoscopic surgeries. Management expects higher unit growth with smaller pieces, but stabilization will depend on the balance between procedure types and market trends.
Q:What is the impact of the new account targeting strategy?
A:The new strategy focuses on deeper penetration within existing accounts by engaging more surgeons per site and leveraging the full product portfolio. This approach aims to create 'stickiness' and reduce reliance on single users in geographically dispersed areas.
Q:What is the impact of weather and external factors on Q1 performance?
A:Weather disruptions, including storms on the East Coast, and low volumes in January contributed to a slow start in Q1. Some elective procedures were deferred or lost, impacting performance.
Q:What gives management confidence in achieving the back-end loaded guidance?
A:Confidence is based on factors such as a fully staffed sales force, new product launches, and the expected productivity ramp of new reps. Historical patterns of quarter-to-quarter growth also support the guidance.
Q:How are different product lines expected to perform in 2026?
A:OviTex sales are expected to grow, supported by strong European performance. PRS sales are anticipated to increase with new product launches, and LIQUIFIX is expected to grow from a smaller base. The focus is on leveraging the full portfolio to drive growth.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific reasons for the significant reduction in guidance from 15% to 8%, beyond emphasizing prudence and the complexity of organizational changes. They also did not provide firm data on the impact of weather disruptions on Q1 performance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Demand
Full
LIQUIFIX
PRS
ability
account relationship
adoption
approach
body
caliber
candidate profile
cohort
comp plan
contribution
core
customer
discipline
education
emphasis
hire
hiring
inflection
infrastructure
investment sale
marketing focus
month
productivity
promotion
ramp
recruitment
relationship acumen
rep TELA
rep investment
restructuring
sale enablement
sale talent
sale training
share
summary
talent profile
team
tenure
TELA Transcript
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reflects mixed signals. While there are improvements in losses and cash flexibility, the reduced guidance and uncertainties due to organizational changes and external factors like weather impact sentiment negatively. The Q&A highlighted management's cautious approach and lack of clarity in some responses, further contributing to a neutral outlook. The absence of strong positive catalysts or partnerships limits the potential for a significant stock price increase.
TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals a mixed performance, with stable gross margins and reduced losses but lowered guidance for 2025, indicating potential challenges. The Q&A highlights uncertainties, particularly with unclear management responses and the need for refinancing and equity raises, suggesting financial strain. Despite some positive growth in Europe and a strong sales force, the lack of precise future growth details and a lowered guidance contribute to a negative sentiment, likely impacting the stock price negatively in the short term.
TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call indicates strong financial performance with reduced losses and consistent sales growth. The Q&A section supports this with plans for sales force expansion and strategic focus on new product launches and market positioning. Despite some expenses rising, the overall financial health appears stable. Additionally, management's confidence in meeting guidance and increased focus on patient-centric culture and reinforced tissue matrix contracts suggest positive future prospects. The lack of any major risks or uncertainties in management responses further supports a positive sentiment.
TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript
Unknown5-11
The earnings call presents a mixed outlook. Positive aspects include strong revenue growth projections and a strategic shift towards natural repair products. However, challenges such as tariff impacts, increased losses, and lack of a share repurchase program balance the positives. The Q&A reveals management's uncertainty regarding tariffs and competitive pressures. The market may react cautiously, resulting in a neutral stock price movement over the next two weeks.
TELA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
